We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Emodin Exerts an Antiapoptotic Effect on Human Chronic Myelocytic Leukemia K562 Cell Lines by Targeting the PTEN/PI3K-AKT Signaling Pathway and Deleting BCR-ABL.
- Authors
Wang, Chun-Guang; Zhong, Liang; Liu, Yong-Li; Shi, Xue-Jun; Shi, Long-Qin; Zeng, Li; Liu, Bei-Zhong
- Abstract
The BCR-ABL kinase inhibitor, imatinib mesylate, is the front-line treatment for chronic myeloid leukemia, but the emergence of imatinib resistance has led to the search for alternative drug treatments. There is a pressing need, therefore, to develop and test novel drugs. Natural products including plants, microorganisms, and halobios provide rich resources for discovery of anticancer drugs. In this article, we demonstrate that emodin inhibited the growth of K562 cells harboring BCR-ABL in vitro and in vivo, and induced abundant apoptosis, which was correlated with the inhibition of PETN/PI3K/Akt level and deletion of BCR-ABL. These findings suggest that emodin is a promising agent to kill K562 cells harboring BCR-ABL.
- Subjects
TREATMENT of chronic myeloid leukemia; ANIMAL experimentation; ANTINEOPLASTIC agents; APOPTOSIS; BIOLOGICAL products; CELL lines; CELLULAR signal transduction; HERBAL medicine; CHINESE medicine; MICE; IMATINIB; PROTEIN kinase inhibitors; IN vitro studies; IN vivo studies
- Publication
Integrative Cancer Therapies, 2017, Vol 16, Issue 4, p526
- ISSN
1534-7354
- Publication type
Article
- DOI
10.1177/1534735416664784